Stocktoria

REGENEREX PHARMA, INC. RGPX

OTC · stock · Pharmaceutical Preparations · website · IPO 2008-09-08

REGENEREX PHARMA, INC. financials (annual, from 10-K)

Revenue
2014201420182019202020212022202320242025
Net income
2014201420182019202020212022202320242025
Free cash flow
2014201420182019202020212022202320242025

Bars are annual figures from 2014 to 2025; red bars are negative (a loss or cash outflow).

MetricFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2014FY2014
Revenue$1,775$2,608$9,239
Gross profit-$244,917$896
R&D expense$662,479$2.4M
SG&A expense$1.2M$1.1M
Operating income-$1.8M-$3.5M-$96,171-$126,267-$43,411-$77,003-$91,734-$49,451
Interest expense$320,047$80,638$66,788$59,063$42,905$28,658$778$3,556$10,438
Income tax-$2,717
Net income-$2.5M-$3.5M-$137,330-$195,591-$353,752$111,589-$93,579-$49,671$859,827-$981,181
Operating cash flow-$1.6M-$457,548-$76,164-$69,922-$62,652-$291,179$47,059$36,122-$71,641-$255,264
Cash & equivalents$653,025$372$1,135$2,640$6,902$5,460$88,546$1,728$1,319$11,560
Inventory$246,691
Total assets$1.3M$766,680$6,539$15,322$10,470$259,167$105,623$15,069$3,819$14,893
Total liabilities$5.4M$4.8M$1.1M$1.0M$845,496$740,441$475,308$336,175$799,214
Shareholders' equity-$4.2M-$4.1M-$1.1M-$985,617-$835,026-$481,274-$369,685-$321,106-$795,395-$742,706

Growth · year-over-year · Revenue CAGR -56.2%

MetricFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2014FY2014
Revenue growth-31.9%
Net income growth-417.0%-105.8%

Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.

Source: SEC EDGAR filings · CIK 0001357878 · US · as of 2025-03-31. facts plus Stocktoria's own computed scores — not investment advice.